Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 54

Results For "WHO"

2860 News Found

AstraZeneca Pharma India receives permission to import Durvalumab Solution
News | July 02, 2025

AstraZeneca Pharma India receives permission to import Durvalumab Solution

Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy


Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer
Clinical Trials | July 01, 2025

Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer

New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options


Briefs: Lyfius Pharma and Aurobindo Pharma
News | July 01, 2025

Briefs: Lyfius Pharma and Aurobindo Pharma

Lyfius Pharma restarts operations at Penicillin-G manufacturing facility


Fredun Pharmaceuticals acquires One Pet Stop to foray into pet care market
Healthcare | June 30, 2025

Fredun Pharmaceuticals acquires One Pet Stop to foray into pet care market

The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028


Briefs: Neuland Laboratories and Granules India
Drug Approval | June 29, 2025

Briefs: Neuland Laboratories and Granules India

Granules India receives 1 observation from USFDA for Chantilly facility


Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr
News | June 29, 2025

Torrent Pharma to acquire KKR’s stake in JB Pharma for Rs. 25,689 Cr

Acquisition to be followed by merger; strengthens Torrent’s IPM market presence


FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels
Drug Approval | June 28, 2025

FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels

Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access


Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Biotech | June 26, 2025

Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series

The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability